ReviewClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2010
Liver disease in the HIV-infected individual.
Review in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05023044 (Nonalcoholic Fatty Liver Disease In Persons Living With HIV Database Study), which is not on this map. Cited by 117 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Nonalcoholic Fatty Liver Disease In Persons Living With HIV Database Study
Who cites it
117 citing papers in PubMed, 3 syntheses or guidelines pooled it, 197 citations in OpenAlex.
- The global prevalence and impact of steatotic liver disease and viral infections: A systematic review and meta-analysis.Hepatology communications · 2025Pooled it
- Prevalence of hypertension among patients aged 50 and older living with human immunodeficiency virus.Medicine · 2019Pooled it
- A systematic review of hepatic tuberculosis with considerations in human immunodeficiency virus co-infection.BMC infectious diseases · 2015Pooled it
- Increased Prevalence of Hepatic Steatosis in Young Adults With Lifelong HIV.The Journal of infectious diseases · 2019Trial
- Hepatotoxicity During Isoniazid Preventive Therapy and Antiretroviral Therapy in People Living With HIV With Severe Immunosuppression: A Secondary Analysis of a Multi-Country Open-Label Randomized Controlled Clinical Trial.Journal of acquired immune deficiency syndromes (1999) · 2018Trial
- Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2017Trial
- Higher plasma kynurenine-tryptophan ratio predicts incident hepatic fibrosis in women with HIV.AIDS (London, England) · 2026Article
- Subtype-Specific Mortality and Cardiovascular Burden in HIV Patients with Steatotic Liver Disease: A Korean National Cohort Study.Gut and liver · 2026Article
- Metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated alcohol-related liver disease in human immunodeficiency virus.World journal of virology · 2026Review
- Prevalence and Correlates of Steatotic Liver Disease Among People With HIV in Uganda.Open forum infectious diseases · 2026Article
- Article
- Article
- Prevalence and Spectrum of Chronic Liver Disease Among Patients Seeking Health Care in Ghana.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Lipid Profile Differences in HIV-Infected Populations With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis.Chronic diseases and translational medicine · 2026Article
- The Effect of Short-Term and High-Intensity Functional Circuit Training on Plasma Lipidome Profiles of People Living with and Without HIV.Metabolites · 2025Article
- Article
- Trends and disparities in human immunodeficiency virus and chronic liver disease mortality in the United States: A nationwide analysis.The Journal of international medical research · 2025Article
- Article
- Pharmacokinetics of islatravir in participants with moderate hepatic impairment.Antimicrobial agents and chemotherapy · 2025Article
- Optimizing cardiometabolic risk in people living with human immunodeficiency virus: A deep dive into an important risk enhancer.American journal of preventive cardiology · 2024Review
57 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Since the advent of effective antiretroviral therapy (ART) for human immunodeficiency virus-1 (HIV), there has been a substantial decrease in deaths related to acquired immunodeficiency syndrome (AIDS). However, in the ART era, liver disease is now the most common non-AIDS-related cause of death among HIV-infected patients, accounting for 14%-18% of all deaths in this population and almost half of deaths among hospitalized HIV-infected patients. Just as the burden of non-AIDS morbidity and mortality has changed in the ART era, the types of liver disease the clinician is likely to encounter among these patients have changed as well. This review will discuss the causes of liver disease in the HIV-infected population in the ART era, including chronic hepatitis C virus, chronic hepatitis B virus, medication-related hepatotoxicity, alcohol abuse, nonalcoholic fatty liver disease, and AIDS-related liver diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.